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NF-κBTRAF6 plays a crucial role in signal transduction of the Toll-like receptor (TLR). It has been reported that
TRAF6 catalyzes the formation of unique Lys63-linked polyubiquitin chains, which do not lead to
proteasome-mediated degradation. Here we found that stimulation of J774.1 cells with various TLR ligands
led to decreases in TRAF6 protein levels that occurred at a slower rate than IκBα degradation. The decrease
in TRAF6 was inhibited by proteasome inhibitors MG-132, lactacystin and N-acetyl-leucyl-leucyl-norleucinal.
Among intracellular TLR signaling molecules MyD88, IRAK-4, IRAK-1, TRAF6, and IKKβ, only IRAK-1 expres-
sion downregulated TRAF6 in HEK293 cells. The amount of TRAF6 expressed either transiently or stably
was also reduced by co-expression of IRAK-1 and no TRAF6 cleavage products were detected. The levels of
either a TRAF6 N-terminal deletion mutant or a ubiquitin ligase-defective mutant were not affected by
IRAK-1 expression. Downregulation of TRAF6 required the TRAF6-binding site (Glu544, Glu587, Glu706) of
IRAK-1 but not its catalytic site (Asp340). Upon IRAK-1 transfection, no signiﬁcant TRAF6 ubiquitination
was detected. Instead, TRAF6-associated IRAK-1 was ubiquitinated with both Lys48- and Lys63-linked
polyubiquitin chains. TRAF6 downregulation was inhibited by co-expression of the E3 ubiquitin ligase Pellino
3, whose Lys63-linked polyubiquitination on IRAK-1 is reported to compete with Lys48-linked IRAK-1
polyubiquitination. Expression of IRAK-1 inhibited IκBα phosphorylation in response to TLR2 stimulation.
These results indicate that stimulation of TLRs induces proteasome-dependent downregulation of TRAF6.
We conclude that TRAF6 associated with ubiquitinated IRAK-1 is degraded together by the proteasome and
that IRAK-1 possesses a negative regulatory role on TLR signaling.
© 2011 Elsevier B.V. All rights reserved.1. Introduction
Toll-like receptor (TLR)/interleukin-1 receptor (IL-1R) family
members share common intracellular signaling proteins, including
the adaptor protein MyD88, the IL-1R-associated kinase (IRAK) family
and TRAF6 [1–2]. Ligand binding triggers the recruitment of MyD88
to the Toll/IL-1 receptor domain (TIR) of TLR/IL-1R through a TIR–
TIR interaction, which in turn recruits IRAK-4 and IRAK-1 to the re-
ceptor complex. IRAK-4 does not bind IRAK-1 directly but is recruited
into the complex following binding by MyD88. When IRAK-1 and
IRAK-4 come in close proximity, IRAK-4 phosphorylates IRAK-1 [3].
Phosphorylated IRAK-1 then interacts with TRAF6 [4]. Upon dissocia-
tion from the receptor complex, TRAF6 and IRAK-1 join a complexcinal; IRAK, IL-1R-associated
s; TLR, Toll-like receptor; TIR,
of Pharmaceutical Sciences,
-shi, Tokyo 202-8585, Japan.
amoto).
rights reserved.consisting of TAK1, TAB1 and TAB2 at the plasma membrane [5–7].
This interaction induces phosphorylation of TAB2 and TAK1, which
then translocate together with TRAF6 and TAB1 to the cytosol.
Meanwhile, IRAK-1 remains at the membrane, where it is degraded,
probably by a ubiquitin-dependent mechanism [8]. The complex
composed of TRAF6, TAB1, TAB2 and TAK1 then associates with the
ubiquitin-conjugating enzyme complex Ubc13-Uev1A [9] whereupon
TRAF6 is ubiquitinated, which induces the activation of TAK1.
Activated TAK1 then phosphorylates the IKK complex, leading to
NF-κB activation [10].
IRAK-1 consists of an N-terminal death domain, which is implicated
in binding to MyD88 [11], and a central serine/threonine kinase
domain. Although the kinase activity of IRAK-1 is strongly induced
upon TLR/IL-1R stimulation, this kinase activity or even the entire
kinase domain is reported to be dispensable for signaling through
NF-κB activation [12-15]. In this context, IRAK-1 may act as a recruiting
protein rather than a kinase. The C-terminal region of IRAK-1 contains
three potential TRAF6-binding sites andmutation of glutamate residues
(Glu544, Glu587, Glu706) in these sites to alanine greatly reduces NF-κB
activation [16]. The death domain and the internal domain (between
the death domain and the kinase domain) of IRAK-1 are also involved
in TRAF6 binding, and the N-terminal region (death domain and
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cient for IL-1-induced activation of NF-κB [15].
Upon IL-1R/TLR stimulation, IRAK-4 phosphorylates IRAK-1 [17],
which probably triggers autophosphorylation of IRAK-1. IRAK-1
autophosphorylation promotes its ubiquitination and subsequent
proteasomal degradation [8, 14]. In the ubiquitin-proteasome path-
way, proteins destined for degradation receive polyubiquitin chains,
in which ubiquitin molecules are typically linked through Lys48[18].
Such ubiquitinated proteins are recognized and degraded by the 26S
proteasome [19]. Polyubiquitination of TRAF6 is also considered to
be important for TLR/IL-1R signaling [20]. In conjunction with the
ubiquitin-conjugating enzyme complex Ubc13-Uev1A, TRAF6 func-
tions as a ubiquitin ligase that catalyzes the formation of unique
Lys63-linked polyubiquitin chains [9–10]. Unlike Lys48-linked ubiqui-
tination, Lys63-linked ubiquitination does not promote effective deg-
radation [21–22]. TRAF6 catalyzes Lys63-linked polyubiquitination on
TRAF6 itself. This polyubiquitinated TRAF6 appears not to be targeted
for degradation [23], but instead activates NF-κB signaling proteins by
a proteasome-independent mechanism [9–10].
In this study, we found that stimulation of TLRs leads to
proteasome-dependent downregulation of TRAF6 through interaction
with IRAK-1 and provided the ﬁrst evidence to show a negative regu-
latory role of IRAK-1 on TLR signaling.
2. Materials and methods
2.1. Cell culture and reagents
The HEK293 and J774.1 cell lines (both obtained from the Human
Science Research Resources Bank, Tokyo, Japan) were grown in
DMEM (Invitrogen, Carlsbad, CA) supplemented with 10% (v/v)
heat-inactivated fetal calf serum (Invitrogen, Carlsbad, CA), penicillin
(100 U/ml), and streptomycin (100 μg/ml). To create a stable cell line
expressing FLAG-tagged TRAF6, an expression plasmid encoding
FLAG-tagged TRAF6 was linearized with BglII and transfected into
HEK293 cells by calcium phosphate precipitation. Resistance to
G418 (1 mg/ml) was used to select transfected cells. A polyclonal an-
tiserum against the EIAV-tag epitope (amino acid sequence: ADRR-
IPGTAEE) was a kind gift from Dr. Nancy Rice (NCI-Frederick Cancer
Research and Development Center). Antibodies against TRAF6 (H-
274; Santa Cruz Biotechnology, Santa Cruz, CA), ubiquitin (H-1904;
Santa Cruz Biotechnology, Santa Cruz, CA), FLAG-epitope (M2;
Sigma-Aldrich, St. Louis, MO), HA-epitope (InvivoGen, San Diego,
CA), phosphorylated (Ser32/36) IκBα (5A5; Cell Signaling Technology,
Danvers, MA) and β-actin (AC-15; Sigma-Aldrich, St. Louis, MO) were
used. MG-132, lactacystin and N-acetyl-leucyl-leucyl-norleucinal
(ALLN) were purchased from Wako Pure Chemical Industries
(Osaka, Japan), Peptide Institute (Osaka, Japan) and Sigma-Aldrich
(St. Louis, MO), respectively. Anti-FLAG M2 afﬁnity gel and anti-HA
afﬁnity gel were from Sigma-Aldrich (St. Louis, MO). Tripalmitoyl-
Cys-Ser-Lys-Lys-Lys-Lys (Pam3CSK4) and MALP-2 were obtained
from Bachem (Bubendorf, Switzerland) and suspended in 25 mM
octyl glucoside. E. coli O111:B4 LPS was obtained from Sigma
(St. Louis, MO) and re-puriﬁed according to the method described
by Hirschfeld et al. [24]. Poly(I:C) was purchased from GE Healthcare
(Amersham Place, UK). Imiquimod and single-stranded RNA
(ssRNA40) were from InvivoGen (San Diego, CA). CpG oligodeoxynu-
cleotide (CpG ODN 5001) was synthesized at Operon Biotechnologies
(Tokyo, Japan).
2.2. Plasmids
RT-PCR was used to amplify the coding regions of human IRAK-4
and IKK from total RNA prepared from THP-1 cells, while MyD88
was ampliﬁed from human spleen RNAs (OriGene Technologies,
Rockville, MD). Human TRAF6 and ubiquitin coding regions wereampliﬁed from a human spleen cDNA library (Clontech, Palo Alto,
CA). Plasmids containing human IRAK-1 and an N-terminal segment
of Pellino 3 were obtained from the Mammalian Gene Collection
with any existing deletions in the IRAK-1 plasmid corrected by PCR-
mediated mutagenesis. The Pellino 3 C-terminus was ampliﬁed by
RT-PCR from total RNA prepared from THP-1 cells and the Pellino 3
N- and C-termini were joined at the EcoNI site. The coding regions
of all constructs described above were subcloned into mammalian
expression vectors containing the N-terminal EIAV-tag, HA-tag or
FLAG-tag epitope sequence. The NF-κB-dependent luciferase
reporter plasmid pELAM-L was described previously [25]. All mutant
plasmids were created by PCR-mediated mutagenesis and the muta-
tions conﬁrmed by DNA sequencing.
2.3. NF-κB reporter assay, immunoprecipitation and immunoblotting
The NF-κB-dependent luciferase reporter assay was performed as
previously described [26]. Brieﬂy, HEK293 cells (2–5×105 cells)
were plated in 6-well plates and transfected on the following day
by calcium phosphate precipitation with the indicated plasmids to-
gether with 0.2 μg pELAM-L and 5 ng phRL-TK (Promega, Madison,
WI) for normalization. At 24–32 h after transfection, lysis buffer
(10 mM HEPES-KOH, pH 7.9, 10 mM KCl, 5 mM EDTA, 40 mM β-
glycerophosphate, 0.5% NP-40, 30 mM NaF, 1 mM Na3VO4) containing
a protease inhibitor cocktail (Roche Diagnostics, Mannheim, Germany)
was added for cellular extract preparation. For detection of ubiquiti-
nated proteins, the lysis buffer was supplemented with 10 mM
iodoacetamide. A portion of the cellular extract was used for reporter
gene activity measurement using Dual-Luciferase Reporter Assay
System according to the manufacturer's instructions (Promega,
Madison, WI). Anti-FLAG M2-agarose was added to another cellular
extract aliquot, incubated at 4 °C for 1 h, and the agarose was washed
three times with PBS containing 0.5% Nonidet P-40. Bound proteins
were eluted from the agarose by incubating with 1% SDS. The superna-
tant was subjected to SDS-PAGE as described previously [27]. For dou-
ble immunoprecipitation studies, the supernatant was boiled for
5 min, diluted ten-fold with PBS containing 0.5% Nonidet P-40 and
immunoprecipitated with anti-HA agarose. The agarose was washed
three times with PBS containing 0.5% Nonidet P-40, and bound proteins
were eluted by incubation with 1% SDS. Proteins were then transferred
to a polyvinylidene diﬂuoride membrane (Immobilon-P; Millipore,
Bedford, MA) for immunoblotting with the indicated antibodies
followed by visualization using an enhanced chemiluminescence
system (GE Healthcare, Amersham Place, UK).
3. Results
3.1. TLR stimulation leads to proteasome-dependent downregulation of
TRAF6
Upon stimulation of the mouse macrophage-like cell line J774.1
with various TLR ligands, we found that TRAF6 protein levels were de-
creased (Fig. 1A). Stimulation of J774.1 cells for 24 h with Pam3CSK4
(TLR1/2 ligand),MALP-2 (TLR2/6 ligand), LPS (TLR4 ligand), Imiquimod
(TLR7 ligand), ssRNA40 (TLR8 ligand) and CpG ODN (TLR9 ligand) de-
creased TRAF6 protein levels as detected by immunoblotting (Fig. 1A,
upper and bottom panels). Addition of poly(I:C) only minimally affect-
ed TRAF6 levels, although inducible phosphorylation of IκBα at Ser32
and Ser36 (Fig. 1A, second panel) was observed. Since IκBα is known
to be inducibly degraded by the proteasome in response to TLR stimula-
tion, the level of IκBα protein was also examined. Although poly(I:C)
did not induce efﬁcient TRAF6 decreases, it decreased IκBα levels
(Fig. 1A third panel). Interestingly, LPS induced IκBα phosphorylation
to an extent higher than that of Imiquimod and CpG ODN (Fig. 1A sec-
ond panel, compare lanes 5, 6 and 8) but only weakly decreased
TRAF6 levels (Fig. 1A upper and bottom panels). The level of β-actin
Fig. 1. TLR stimulation leads to downregulation of TRAF6. (A) J774.1 cells were either
unstimulated (none) or stimulated with Pam3CSK4 (1 μg/ml), MALP-2 (0.1 μg/ml),
poly(I:C) (10 μg/ml), LPS (100 ng/ml), Imiquimod (50 μM), and ssRNA40 (2 μg/ml)
and CpG ODN 5001 (1 μM), or (B) stimulated with LPS (100 ng/ml) or increasing
concentrations of Pam3CSK4 (1, 10, 100 ng/ml) or CpG ODN 5001 (1, 10, 100 nM) for
24 h. Cellular extracts were subjected to SDS-PAGE followed by immunoblot analyses
for detection of endogenous TRAF6 (top), phosphorylated (Ser32/36) IκBα (second),
IκBα (third) as well as endogenous β-actin (fourth). Densitometric evaluation of
TRAF6 levels normalized to β-actin was shown in the bottom panel.
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ability of Pam3CSK4 and CpG ODN to decrease TRAF6 levels was
concentration-dependent (Fig. 1B, upper and bottom panels). Again,
the level of β-actin was not affected by these stimulations (Fig. 1B,
bottom panel).
Next, we examined the time course proﬁle of TLR stimulation
(Fig. 2). Stimulation of J774.1 cells with Pam3CSK4 and CpG ODN de-
creased TRAF6 levels after 3–8 h, while TRAF6 levels were not signif-
icantly reduced even 8 h after LPS stimulation (Fig. 2A, B, upper and
bottom panels). In contrast, IκBα was signiﬁcantly phosphorylated
and degraded within 5–10 min of stimulation, with IκBα levels grad-
ually recovering due to protein re-synthesis (Fig. 2A, B, second and
third panels). Upon decreases in TRAF6 levels following Pam3CSK4
or CpG ODN stimulation (Fig. 2B), IκBα protein levels recovered to
the prestimulation level and phosphorylation of IκBα decreased.
The β-actin level remained unaffected throughout the experiment
(Fig. 2A, B, bottom panels).
We then explored the involvement of the proteasome in TRAF6
decreases. J774.1 cells were either unstimulated or stimulated with
CpG ODN in the absence or presence of each of three different protea-
some inhibitors, MG-132, lactacystin or ALLN. TRAF6 levels decreased
in response to CpG ODN stimulation in the absence of proteasomeinhibitors, whereas no decrease in TRAF6 level was observed in the
presence of these inhibitors (Fig. 3, upper). The level of β-actin was
not affected by these treatments (Fig. 3, bottom). These results indi-
cate that TLR stimulation leads to proteasome-dependent downregu-
lation of TRAF6 that occurs at a slower rate compared to IκBα
degradation.
3.2. Expression of IRAK-1 leads to downregulation of TRAF6
TLRs share common intracellular signaling proteins and it is well
known that expression of these proteins drives TLR signaling to acti-
vate NF-κB. Thus, we next examined which signaling molecules are
involved in downregulating TRAF6. We expressed MyD88, IRAK-4,
IRAK-1, TRAF6 and IKKβ and examined the level of TRAF6 (Fig. 4A)
in HEK293 cells. With the exception of IRAK-4, all of these proteins
(Fig. 4A, middle) signiﬁcantly activated NF-κB (Fig. 4C), but only
IRAK-1 expression downregulated TRAF6 (Fig. 4A, upper panel). Ex-
pression of IRAK-4 did not induce signiﬁcant activation of NF-κB as
previously reported [28–29] and also caused no downregulation of
TRAF6. Since the antibody against TRAF6 detects both endogenous
as well as exogenously expressed TRAF6, the effect of TRAF6
expression on endogenous TRAF6 levels could not be determined.
Thus, we expressed HA-tagged TRAF6 together with the signaling
molecules described above to examine the effect of these molecules
on the level of TRAF6 expressed (Fig. 4B). The level of expressed
TRAF6 was also decreased only with IRAK-1 expression (Fig. 4B,
upper) while other molecules did not signiﬁcantly affect the level.
The level of β-actin was not affected by any expression (Fig4A, B,
lower). Taken together, these results indicate that downregulation
of TRAF6 is likely to be speciﬁc to IRAK-1.
We next examined the effect of the extent of IRAK-1 expression on
TRAF6 levels (Fig. 5A). As the amount of IRAK-1 expression increased
(Fig. 5A, middle), endogenous TRAF6 levels (Fig. 5A, upper) gradually
decreased, although the level of β-actin was not affected (Fig. 5A,
lower). To conﬁrm this effect, we established a HEK293 cell line that
stably expresses FLAG-tagged TRAF6, and transfected an IRAK-1 ex-
pression plasmid. In these cells, the amount of FLAG-tagged TRAF6
also decreased in proportion to the amount of the IRAK-1 plasmid
transfected (Fig. 5B). To determine whether the decrease in TRAF6
was caused through protease-mediated cleavage of TRAF6, TRAF6
carrying an N-terminal EIAV-tag and a C-terminal HA-tag was tran-
siently expressed in cells and the effect of co-expression with IRAK-
1 was studied (Fig. 5C). Expression of IRAK-1 decreased the amount
of TRAF6 protein detected by either anti-EIAV or anti-HA antibodies
without affecting the β-actin level but no TRAF6 cleavage fragments
were detected by either antibody. The decrease in TRAF6 levels was
not due to reduced traf6 expression as TRAF6 mRNA levels were un-
affected by IRAK-1 expression, as documented by quantitative RT-
PCR (data not shown). These results suggest that the expression of
IRAK-1 leads to TRAF6 degradation.
3.3. Kinase activity of IRAK-1 is not required for TRAF6 downregulation
We next asked whether the kinase activity of IRAK-1 is required to
downregulate TRAF6. HEK293 cells were transfected with expression
plasmids for either wild-type or a kinase-dead mutant (D340N) of
IRAK-1 as well as a TRAF6 expression plasmid. Although the reduction
in TRAF6 levels was slightly weaker than that caused by expression of
wild-type IRAK-1, expression of IRAK-1-D340N also induced
downregulation of TRAF6 (Fig. 6, upper). On the other hand, expres-
sion of an IRAK-1 mutant where the glutamate residues of the IRAK-
1 TRAF6-binding site (Glu544, Glu587, Glu706) were each replaced
with alanine did not downregulate TRAF6 levels. These IRAK-1 mu-
tants were expressed at levels similar to wild-type IRAK-1 (Fig. 6,
middle) and the level of β-actin was not affected (Fig. 6 lower).
Fig. 2. Time-course of TRAF6 downregulation in response to TLR stimulation. J774.1 cells were stimulated with Pam3CSK4 (1 μg/ml), CpG ODN 5001 (1 μM) and LPS (100 ng/ml) for
the indicated time periods (m: min; h: hr). Cellular extracts were subjected to SDS-PAGE followed by immunoblot analyses for detection of endogenous TRAF6 (top), phosphory-
lated (Ser32/36) IκBα (second), IκBα (third), and endogenous β-actin (fourth). Densitometric evaluation of TRAF6 levels normalized to β-actin was shown in the bottom panel.
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TRAF6
The TRAF6 N-terminal region, and in particular Cys70, is essential
for its ubiquitin ligase activity [9]. To examine the role of TRAF6Fig. 3. CpG ODN-induced downregulation of TRAF6 is inhibited by proteasome inhibi-
tors. J774.1 cells were stimulated with (+) or without (−) CpG ODN 5001 (1 μM) in
the presence or absence of 0.7 μM MG-132, 10 μM lactacystin (Lact.) or 30 μMN-
acetyl-leucyl-leucyl-norleucinal (ALLN). After 16 h, cellular extracts were subjected
to SDS-PAGE followed by immunoblot analyses of endogenous TRAF6 (top) and β-
actin (middle). Densitometric evaluation of TRAF6 levels normalized to β-actin was
shown in the bottom panel.ubiquitin ligase activity in IRAK-1-dependent downregulation, we
transfected HEK293 cells with plasmids expressing either wild-type,
an N-terminal deletion mutant of TRAF6 (DN; deletion of amino
acid 2–288) or a ubiquitin ligase-defective mutant of TRAF6 (TRAF6-
C70A), and characterized the effect of IRAK-1 co-expression (Fig. 7).
Expression of IRAK-1 (Fig. 7, lower) caused downregulation of wild-
type TRAF6 but the levels of TRAF6-DN and TRAF6-C70A were not
affected by IRAK-1 expression, indicating that the ubiquitin ligase
activity of TRAF6 is required for IRAK-1-mediated downregulation.
3.5. The proteasome is involved in IRAK-1-induced downregulation of
TRAF6
Since ubiquitin ligase activity was required for downregulation of
TRAF6, we next asked whether the proteasome is involved in IRAK-1-
induced TRAF6 downregulation. HEK293 cells were transfected with
or without an IRAK-1 expression plasmid in the absence or presence
of proteasome inhibitors MG-132, lactacystin or ALLN and the level
of TRAF6 protein was determined (Fig. 8A). Although the β-actin
levels (Fig. 8A, lower) in MG-132-treated cells were slightly lower
due to decreased cell viability, the presence of these proteasome in-
hibitors clearly inhibited downregulation of TRAF6 (Fig. 8A, upper)
in response to IRAK-1 expression (Fig. 8A lower). The effect of varying
concentrations of lactacystin was also examined in cells expressing
FLAG-tagged TRAF6 (Fig. 8B). Expression of IRAK-1 (Fig. 8B, middle)
Fig. 4. Downregulation of TRAF6 is speciﬁc to IRAK-1. HEK293 cells were plated in 6-well plates and transiently transfected with each EIAV-tagged expression plasmid (0.5 μg) for
MyD88, IRAK-4, IRAK-1, TRAF6 and IKKβ without (A) or with (B) an expression plasmid (0.5 μg) for HA-tagged TRAF6. After 30 h, cellular extracts were subjected to SDS-PAGE
followed by immunoblot analyses to detect endogenous TRAF6 (A top), HA-tagged TRAF6 (B top) or EIAV-tagged MyD88, IRAK-4, IRAK-1, TRAF6 and IKKβ (middle) and β-actin
(bottom). NF-κB-dependent reporter activity (mean±S.E.M from three independent experiments) in the extracts was also measured (C).
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treatment with lactacystin inhibited the downregulation in a
concentration-dependent manner (Fig. 8B, upper) without affectingFig. 5. IRAK-1-induced downregulation of TRAF6. An increasing amount (0.01–1 μg) of
EIAV-tagged (A, B) or FLAG-tagged (C) IRAK-1 expression plasmid was transiently trans-
fectedwith (C) orwithout (A, B) an expression plasmid (0.5 μg) for TRAF6 taggedwith N-
terminal EIAV and C-terminal HA epitopes into HEK293 cells (A, C) or HEK293 cells stably
expressing FLAG-tagged TRAF6 (B). After 30 h, cellular extracts were subjected to SDS-
PAGE followed by immunoblot analyses for the detection of endogenous TRAF6 (A top),
FLAG—(B top), EIAV—(C upper left) or HA-tagged (C upper right) TRAF6, EIAV—(A, B
middle) and FLAG-tagged IRAK-1 (C lower left) as well as endogenous β-actin.the β-actin levels (Fig. 8B, lower). These results indicate the involve-
ment of the proteasome in decreased TRAF6 levels.
3.6. IRAK-1 bound to TRAF6 is ubiquitinated
The requirement of TRAF6 ubiquitin ligase activity (Fig. 7) and the
effect of proteasome inhibitors (Fig. 8) suggest the involvement of the
ubiquitin-proteasome system in IRAK-1-induced downregulation of
TRAF6 even though ubiquitinated TRAF6 was not considered to be a
proteasome target [23]. Thus, we next asked whether TRAF6 is ubi-
quitinated in response to IRAK-1 expression. Either MyD88 or IRAK-
1 was co-expressed in HEK293 cells stably expressing FLAG-tagged
TRAF6 and cellular extracts were prepared from these cells. FLAG-
tagged TRAF6 was then immunoprecipitated with anti-FLAG M2
afﬁnity gel and ubiquitination was detected by an anti-ubiquitin anti-
body. No ubiquitination was observed by transfection of an empty
vector or a MyD88 expression plasmid (Fig. 9, left upper) although
FLAG-tagged TRAF6 was efﬁciently immunoprecipitated (Fig. 9, left
lower). On the other hand, ubiquitination was clearly detected in
response to IRAK-1 expression (Fig. 9, left upper).
Under these experimental conditions, proteins that associate with
TRAF6 were also co-immunoprecipitated. Therefore, to determine
whether TRAF6 itself was actually ubiquitinated, the immunoprecipi-
tated proteins were boiled in the presence of 1% SDS to disrupt non-
covalent protein-protein interactions, and FLAG-tagged TRAF6 was
immunoprecipitated again after the SDS concentration was lowered
to 0.1%. Precipitated TRAF6 was then subjected to immunoblotting
analyses to detect ubiquitination. Efﬁcient polyubiquitination of
TRAF6 was not observed in response to IRAK-1 expression (Fig. 9Fig. 6. Downregulation of TRAF6 requires the putative TRAF6 binding motifs but not
kinase activity of IRAK-1. HEK293 cells were plated in 6-well plates and transiently
transfected with an increasing amount (0.1–0.5 μg) of each expression plasmid for
EIAV-tagged wild-type (wt) IRAK-1, kinase-dead IRAK-1 (KD: D340N) or IRAK-1 lacking
putative TRAF6 binding motifs (dTB: E544A, E587A, E706A) together with an expression
plasmid (0.5 μg) for FLAG-tagged TRAF6. After 30 h, cellular extracts were subjected to
SDS-PAGE followed by immunoblot analyses of FLAG-tagged TRAF6 (top), EIAV-tagged
IRAK-1, IRAK-1 mutants (middle) and endogenous β-actin (bottom).
Fig. 7. Ligase activity of TRAF6 is required for IRAK-1-induced downregulation. HEK293
cells were plated in 6-well plates and transiently transfected with each expression
plasmid (0.5 μg) for EIAV-tagged wild-type (wt) TRAF6, TRAF6 lacking the cysteine
(C70A) critical for its E3 ubiquitin ligase activity or lacking its N-terminal RING and
zinc-ﬁnger domain (DN) with (+) or without FLAG-tagged IRAK-1 expression plasmid
(0.5 μg). After 30 h, cellular extracts were subjected to SDS-PAGE followed by immuno-
blot (IB) analyses for the detection of EIAV-TRAF6, TRAF6 mutants (top), FLAG-tagged
IRAK-1 (middle) and endogenous β-actin (bottom).
Fig. 9. IRAK-1 bound to TRAF6 is ubiquitinated. HEK293 cells stably expressing FLAG-
tagged TRAF6 were plated in 9 cm dishes and transfected either without or with a plas-
mid encoding HA-tagged MyD88 (0.5 μg) or IRAK-1 (0.1 μg), and cellular extracts were
prepared. FLAG-tagged TRAF6 was then immunoprecipitated (IP) with anti-FLAG M2
afﬁnity gel, and the immunoprecipitated protein was divided into three portions.
One portion was subjected to SDS-PAGE followed by immunoblot analyses (IB) for
the detection of ubiquitination (left upper) and FLAG-tagged TRAF6 (left lower) with
anti-ubiquitin and anti-FLAG antibodies, respectively. Another portion was boiled in
the presence of 1% SDS to disrupt non-covalent protein–protein interactions, and
FLAG-tagged TRAF6 was immunoprecipitated again after the SDS concentration was
lowered to 0.1%. Precipitated TRAF6 was then subjected to immunoblotting analyses
for the detection of its ubiquitination (middle upper) and FLAG-tagged TRAF6 (middle
lower) with anti-ubiquitin and anti-FLAG antibodies, respectively. The remaining
protein sample was also boiled in the presence of 1% SDS to release co-precipitated
proteins. Then, co-precipitated HA-tagged protein was immunoprecipitated with
anti-HA afﬁnity gel after the SDS concentration was lowered to 0.1% and subjected to
immunoblotting analyses for the detection of ubiquitination (right, upper) and HA-
tagged proteins (right, lower) by anti-ubiquitin and anti-HA antibodies, respectively.
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(Fig. 9 middle lower).
Because no clear TRAF6 polyubiquitination was observed in re-
sponse to IRAK-1 expression, the polyubiquitination observed in
Fig. 9 (left) was likely to be associated with proteins that co-
precipitated with TRAF6. Since IRAK-1 reportedly interacts with
TRAF6 [4], we next examined ubiquitination of TRAF6-associated
IRAK-1. HEK293 cells stably expressing FLAG-tagged TRAF6 were
co-transfected with plasmids expressing either HA-tagged MyD88
or IRAK-1, and cellular extracts were prepared from these cells.
FLAG-tagged TRAF6 was immunoprecipitated with anti-FLAG M2
afﬁnity gel and the immunoprecipitated protein was boiled in the
presence of 1% SDS to release co-precipitated proteins. Finally, co-
precipitated HA-tagged protein was immunoprecipitated with anti-Fig. 8. IRAK-1-induced downregulation of TRAF6 is inhibited by proteasome inhibitors.
HEK293 cells were plated in 6-well plates and transiently transfected with (+ in A,
lanes 2–6 in B) or without (− in A, lane 1 in B) an expression plasmid (0.5 μg) for
EIAV-tagged IRAK-1 together with a plasmid for FLAG-tagged TRAF6 (B) in the pres-
ence or absence of 5 μM MG-132, 10 μM lactacystin (Lact.), or 50 μMN-acetyl-leucyl-
leucyl-norleucinal (ALLN) in A, or increasing concentrations of lactacystin (Lact.; 1, 2,
5, 10 μM). After 30 h, cellular extracts were subjected to SDS-PAGE followed by immu-
noblot analyses of endogenous TRAF6 (A, top) or FLAG-tagged (B, top), EIAV-tagged
IRAK-1 (middle) and endogenous β-actin (bottom).HA afﬁnity gel after the SDS concentration was lowered to 0.1%
and the resulting proteins were subjected to immunoblotting ana-
lyses of ubiquitination using an anti-ubiquitin antibody. MyD88 was
not co-precipitated with TRAF6 (Fig. 9, right lower), whereas co-
precipitation of IRAK-1 was observed and polyubiquitination of co-
precipitated IRAK-1 was clearly detected (Fig. 9, right upper).
If IRAK-1 interacting with TRAF6 was to undergo Lys48-linked
polyubiquitination, it would be targeted for proteasomal degradation,
and, by association, TRAF6 would also be degraded. However, IRAK-1-
induced downregulation of TRAF6 requires the ubiquitin ligase activ-
ity of TRAF6, which instead catalyzes Lys63-linked polyubiquitination.
As such, we attempted to determine which type of polyubiquitination
occurred on IRAK-1. We examined the ubiquitination of IRAK-1 asso-
ciated with TRAF6 using ubiquitin mutants, in which all Lys residues
or all Lys except Lys48 or Lys63 were mutated to Arg. HEK293 cells sta-
bly expressing FLAG-tagged TRAF6 were then transfected with
expression plasmids encoding either wild-type EIAV-tagged ubiquitin
or its mutants together with HA-tagged MyD88 or IRAK-1, and cellu-
lar extracts were prepared from these cells. FLAG-tagged TRAF6 was
then immunoprecipitated with anti-FLAG M2 afﬁnity gel and the
immunoprecipitated proteins were boiled in the presence of 1% SDS
to release co-precipitated proteins. Finally, co-precipitated HA-
tagged protein was immunoprecipitated with anti-HA afﬁnity gel
after lowering the SDS concentration to 0.1% and the resulting pro-
teins were subjected to immunoblotting analyses to detect ubiquiti-
nation status using an anti-EIAV antibody (Fig. 10). Upon expression
of either wild-type ubiquitin or a ubiquitin mutant in which all of
Lys except Lys48 (48 K) were mutated to Arg, signiﬁcant
Fig. 10. IRAK-1 bound to TRAF6 is ubiquitinated through both Lys48- and Lys63-linked
polyubiquitin chains. HEK293 cells stably expressing FLAG-tagged TRAF6 were plated
in 9 cm dishes and transfected with a plasmid (1.5 μg) encoding wild-type (wt)
EIAV-tagged ubiquitin or its mutants, in which all of Lys (R) or all of Lys except Lys48
(48 K) or Lys63 (63 K) were mutated to Arg together with (+) or without a plasmid
(0.1 μg) encoding HA-tagged IRAK-1, and cellular extracts were prepared from these
cells. One portion of the extracts was subjected to SDS-PAGE followed by immunoblot
analyses (IB) to detect expression of ubiquitin and its mutants with an anti-EIAV anti-
body (bottom). For another extract portion, FLAG-tagged TRAF6 was immunoprecipi-
tated (IP) with anti-FLAG M2 afﬁnity gel and the immunoprecipitated protein was
boiled in the presence of 1% SDS to release co-precipitated proteins. Finally, co-
precipitated HA-tagged protein was immunoprecipitated with anti-HA afﬁnity gel
after the SDS concentration was lowered to 0.1% and was subjected to immunoblotting
(IB) analyses to detect ubiquitination (top) and HA-tagged IRAK-1 (middle) by anti-
EIAV and anti-HA antibodies, respectively.
Fig. 12. TLR2 signaling is inhibited in IRAK-1-expressing cells. HEK293 cells were plated
in 6-well dishes and transfected with plasmids encoding TLR2 (0.1 μg) with or without
a plasmid for IRAK-1 (0.5 μg). After 24 h, cells were stimulated with increasing concen-
trations of Pam3CSK4 (0.01, 0.1, 1, 10 μg/ml) for 1 h. Cellular extracts were subjected to
SDS-PAGE followed by immunoblot analyses for the detection of phosphorylated
(Ser32/36) IκBα (top), IκBα (second), endogenous TRAF6 (third), HA-tagged IRAK-1
(fourth) and endogenous β-actin (bottom).
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ubiquitination was also observed when a ubiquitin mutant, in which
all of Lys except Lys63 (63 K) were mutated to Arg, was expressed.
On the other hand, when a ubiquitin mutant, in which all of the Lys
were mutated to Arg (R), almost no polyubiquitination was observed
although a similar amount of IRAK-1 was co-precipitated with TRAF6
(Fig. 10, middle) and the wild-type and Lys-mutated ubiquitin was
comparably expressed (Fig. 10, lower).
Next, we asked whether IRAK-1 ubiquitination is involved in
IRAK-1-induced downregulation of TRAF6. To address this, we exam-
ined the effect of Pellino 3 on IRAK-1-induced downregulation of
TRAF6. Pellino 3 is reported to promote Lys63-linked polyubiquitina-
tion on IRAK-1 by competing with Lys48-linked IRAK-1 polyubiquiti-
nation [30]. HEK293 cells were expressed with FLAG-tagged TRAF6
and an increasing amount of HA-tagged IRAK-1 with or without
Pellino 3. Cellular extracts were then prepared and TRAF6 and IRAK-1
were detected with anti-FLAG and anti-HA antibodies, respectively.Fig. 11. IRAK-1-induced downregulation of TRAF6 is inhibited by Pellino 3. HEK293
cells were plated in 6-well dishes and transfected with plasmids encoding FLAG-
tagged TRAF6 (0.5 μg) and HA-tagged IRAK-1 (0.1–0.5 μg) with or without a plasmid
for (0.5 μg) Pellino 3. Then, cellular extracts were subjected to SDS-PAGE followed by
immunoblot analyses for the detection of FLAG-tagged TRAF6 (top), HA-tagged IRAK-
1 (middle) and endogenous β-actin (bottom).When IRAK-1was expressed in the absence of Pellino 3, TRAF6 downre-
gulation was clearly observed, whereas this downregulation was signif-
icantly inhibited in the presence of Pellino 3 (Fig. 11, upper), indicating
the involvement of Lys48-linked IRAK-1 polyubiquitination in TRAF6
downregulation. A diffuse higher molecular weight species of IRAK-1
that may be ubiquitinated IRAK-1 was also detected in the presence of
Pellino 3 (Fig. 11, lower). Taken together, these results indicate that
IRAK-1 associated with TRAF6 undergoes Lys48-linked polyubiquitina-
tion and that TRAF6 associatedwith the ubiquitinated IRAK-1 is degrad-
ed together with IRAK-1 by the proteasome.
3.7. TLR signaling is inhibited in IRAK-1-expressing cells
Since TRAF6 plays a crucial role in signal transduction of the TLR, it
is expected that degradation of TRAF6 in response to IRAK-1 expres-
sion leads to inhibition of TLR signalings. To address this, HEK293
cells were transfected with an expression plasmid for TLR2 together
with an empty vector (Fig. 12, left 5 lanes) or a plasmid for IRAK-1
(Fig. 12, right 5 lanes) and 24 h later stimulated with increasing
concentration of Pam3CSK4. Expression of IRAK-1 (fourth panel)
caused TRAF6 downregulation (third panel) and Pam3CSK4 stimula-
tion induced no phosphorylation of IκBα in these cells although the
stimulation led to IκBα phosphorylation in mock-transfected cells
(top panel), indicating an inhibitory effect of IRAK-1 on TLR signaling.
Almost no changes were observed in IκBα (second panel) and β-actin
(bottom panel) levels.
4. Discussion
This study provides the ﬁrst evidence that IRAK-1 possesses a neg-
ative regulatory role for TLR signaling by downregulating TRAF6.
TRAF6 plays a crucial role in signal transduction of the Toll-like recep-
tor (TLR)/interleukin-1 receptor superfamily. TRAF6 functions as an
E3 ubiquitin ligase that catalyzes the formation of unique Lys63-
linked polyubiquitin chains [9–10], which does not lead to
proteasome-mediated degradation [21–22]. In this study, we found
that stimulation of the mouse macrophage-like cell line J774.1 with
various TLR ligands led to a decrease in the amount of TRAF6 (Fig. 1
and 2), which could be abolished by proteasome inhibitors (Fig. 3).
Among molecules involved in TLR signaling, IRAK-1 caused decreases
in TRAF6 levels (Fig. 4). This IRAK-1-dependent decrease in TRAF6
was also ablated by proteasome inhibitors (Fig. 8), suggesting that
this decrease in response to TLR stimulation and IRAK-1 expression
is caused by a common mechanism that involves the proteasome. A
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ing that TRAF6 mRNA levels were not signiﬁcantly affected in re-
sponse to IRAK-1 expression (data not shown) and no TRAF6
cleavage products were detected (Fig. 5C). Although the ubiquitin li-
gase activity of TRAF6 was required for IRAK-1-induced downregula-
tion (Fig. 7), polyubiquitination of TRAF6 itself is unlikely to be
involved since IRAK-1 expression did not induce efﬁcient TRAF6 ubi-
quitination, but rather ubiquitination of IRAK-1 bound to TRAF6
(Fig. 9). Recently, Conze et al. [31] reported that TRAF6 directly ubi-
quitinates IRAK-1 and Xiao et al. [30] showed that IRAK-1 can be ubi-
quitinated with both Lys48- and Lys63-linked polyubiquitin chains.
Furthermore, Xiao et al. [30] reported that TRAF6 can mediate
Lys48-linked polyubiquitination when UbcH5 was present as the E2
ubiquitin ligase. We also observed that IRAK-1 bound to TRAF6 was
ubiquitinated with both Lys48- and Lys63-linked polyubiquitin chains
(Fig. 10). In addition, when we expressed Pellino 3, which promotes
Lys63-linked polyubiquitination on IRAK-1 by competing with Lys48-
linked IRAK-1 polyubiquitination [30], IRAK-1-induced downregula-
tion of TRAF6 was signiﬁcantly inhibited (Fig. 11). All of these results
indicate that TRAF6-associated IRAK-1 is ubiquitinated by both Lys48-
and Lys63-linked polyubiquitin chains. IRAK-1 modiﬁed with Lys48-
linked polyubiquitination is then degraded by the proteasome and
TRAF6 bound to ubiquitinated IRAK-1 is probably degraded together
with IRAK-1, leading to TRAF6 downregulation.
Recently, Keating et al. [32] reported that IRAK-2 plays a more
central role than IRAK-1 in TLR signaling. They found that expression
of IRAK-2, but not IRAK-1, led to TRAF6 ubiquitination. We also stud-
ied TRAF6 ubiquitination in response to IRAK-2 expression and ob-
served that in non-denaturing immunoprecipitation experiments
where co-precipitation of TRAF6-associated proteins occurs, expres-
sion of IRAK-2 induced more robust TRAF6 ubiquitination (data not
shown) compared to IRAK-1. However, in denaturing immunoprecip-
itation experiments in which only TRAF6 molecules are precipitated,
IRAK-2, like IRAK-1, caused no deﬁnitive ubiquitination of TRAF6
(data not shown). Since Keating et al. [32] observed ubiquitination
under non-denaturing conditions and we observed that IRAK-2 co-
precipitated with TRAF6 was ubiquitinated more efﬁciently than
IRAK-1 (data not shown), the ubiquitination they observed may
have occurred on IRAK-2 or other proteins that co-precipitated with
TRAF6.
The extent and time course of TRAF6 downregulation were not
paralleled with IκBα degradation (Fig. 2). Although various TLR
ligands, including Pam3CSK4, MALP-2, LPS, Imiquimod, ssRNA40 and
CpG ODN (ODN5001) led to downregulation of endogenous TRAF6
levels (Fig. 1), expression of MyD88, IRAK-4, TRAF6 and IKKβ, which
are all involved in TLR/IL-1R signaling, did not affect TRAF6 levels
and downregulation of TRAF6 was speciﬁc to IRAK-1 (Fig. 4). These
results suggest that TLR stimulation may activate an alternate IRAK-
1-dependent and MyD88-independent signaling pathway to downre-
gulate TRAF6. We recently observed that expression of IRAK-1 but not
MyD88 induced formation of oligomers containing both TRAF6 and
IRAK-1 [33]. Thus, the TRAF6 contained in this oligomer may be
degraded together with IRAK-1 by the proteasome. Since TRAF6
downregulation occurred at a slower rate than IκBα degradation,
this downregulation may function as a negative regulatory system
to prevent persistent activation. In fact, the level of IκBα phosphory-
lation decreased when TRAF6 was downregulated (Fig. 2) and IκBα
phosphorylation in response to TLR2 stimulation was inhibited by
expression of IRAK-1 (Fig. 12). TRAF6 plays a crucial role in signal
transduction of the Toll-like receptor (TLR)/interleukin-1 receptor
superfamily. Therefore, clarifying this alternate IRAK-1-dependent
and MyD88-independent signaling pathway may provide new
therapeutic strategies for inﬂammatory diseases that result from
TLR-mediated immune responses.
In conclusion, we found that stimulation of TLRs leads to
proteasome-dependent downregulation of TRAF6 through interactionwith IRAK-1 and provided the ﬁrst evidence to show a negative regu-
latory role of IRAK-1 on TLR signaling.
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